Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

Among adults hospitalized with influenza, Tamiflu treatment on the day of hospital admission was associated with a reduced risk for disease progression.

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

During and after an exacerbation, mental recovery involves taking care of both your physical and mental health. Resting, ...

Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...

Tectonic Therapeutic is a biotechnology company focused on the development of novel therapies for cardiovascular diseases, particularly those involving pulmonary hypertension and heart failure. Its ...

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...

In a world where respiratory issues are increasingly common, finding practical solutions can be daunting. Breathe Drops ...

HealthDay News — In a clinical practice guideline issued by the American Thoracic Society and published in the January issue of the American Journal of Respiratory and Critical Care Medicine, updated ...

A recent trial showed that nicotinamide riboside supplementation might reduce airway inflammation in patients with COPD who ...